Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

NCT03824678 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT03824678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03824678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
February 13, 2019
Completion date
June 18, 2019
Enrollment
40 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, hepatic impairment